<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892020000100004</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tomografía por emisión de positrones asociada con tomografía computarizada en la estadificación de los linfomas]]></article-title>
<article-title xml:lang="en"><![CDATA[Positron emission tomography combined with computed tomography for the staging of lymphomas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fundora Sarraff]]></surname>
<given-names><![CDATA[Teresa Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Reyes]]></surname>
<given-names><![CDATA[Láser Humberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chávez Pérez-Terán]]></surname>
<given-names><![CDATA[Martha Dora]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>36</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892020000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892020000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892020000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Los estudios de imágenes son esenciales para la estadificación de los linfomas. La utilización de la imagen funcional que proporciona la tomografía por emisión de positrones con 18F-2-deoxi-2-fluoro-D-glucosa asociada a la tomografía computarizada ha cambiado fundamentalmente el concepto de estadificación y reestadificación de los linfomas. Constituye una prueba diagnóstica que ha ganado aceptación universal, sobre todo después de la publicación y adopción de las guías de Lugano.  Objetivo:  Analizar la importancia que tienen las imágenes que proporciona la tomografía por emisión de positrones con 18F-2-deoxi-2-fluoro-D-glucosa asociada a la tomografía computarizada en la estadificación actual de los linfomas.  Métodos: Se realizó una revisión bibliográfica, en español y en inglés, de la última década. Se utilizaron los motores de búsqueda de Pubmed, Google y SciELO. Se recolectó y organizó la información siguiendo cronológicamente la aparición de las innovaciones para facilitar la estadificación de los linfomas.  Análisis y síntesis de la información:  Se hace un recorrido desde la introducción de la tomografía computarizada, la tomografía por emisión de positrones y la asociación de estas, hasta su aplicación en el estudio de los linfomas. Se describe la evolución de los sistemas de clasificación para los linfomas y la utilidad del empleo de la tomografía por emisión de positrones con 18F-2-deoxi-2-fluoro-D-glucosa asociada a la tomografía computarizada en la estadificación de los linfomas.  Conclusiones:  Es de gran importancia que, en el momento actual, el manejo óptimo de un paciente con linfoma ávido de 18F-2-deoxi-2-fluoro-D-glucosa incluya la estadificación inicial con tomografía por emisión de positrones asociada con tomografía computarizada. Esto permitirá hacer más precisa la etapificación inicial del paciente, optimizar su tratamiento y evaluación de la terapia implementada; así como un mejor pronóstico y evitar estudios invasivos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Imaging studies are essential for staging of lymphomas. The usage of functional imaging provided by positron emission tomography with 18F-2-deoxy-2-fluoro-D-glucose combined with computed tomography has fundamentally changed the concept of staging and re-staging of lymphomas. It constitutes a diagnostic test that has gained universal acceptance, especially after the publication and adoption of the Lugano guidelines.  Objective:  To analyze the importance of the images provided by positron emission tomography with 18F-2-deoxy-2-fluoro-D-glucose combined with computed tomography in current staging of lymphomas.  Methods:  A bibliographic review was carried out, in Spanish and in English, within the last decade. We used the search engines of Pubmed, Google, and SciELO. The information was collected and organized by chronologically following the origin of the innovations that facilitate the staging of lymphomas.  Information analysis and synthesis:  An analysis is carried out from the introduction of computed tomography, positron emission tomography, and the combination of both, to their application in the study of lymphomas. We described the evolution of lymphoma classification systems and the usefulness of positron emission tomography with 18F-2-deoxy-2-fluoro-D-glucose combined with computed tomography for the staging of lymphomas.  Conclusions:  At the present time, it is of great importance for a patient with lymphoma needing 18F-2-deoxy-2-fluoro-D-glucose to receive optimal management of his or her condition, including initial staging with positron emission tomography combined with computed tomography. This will allow to make the initial staging of the patient more precise, to optimize his or her treatment and evaluation of the implemented therapy, as well as to obtain a better prognosis, avoiding invasive studies.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[linfomas]]></kwd>
<kwd lng="es"><![CDATA[estadificación]]></kwd>
<kwd lng="es"><![CDATA[tomografía por emisión de positrones]]></kwd>
<kwd lng="es"><![CDATA[18F-2-deoxi-2-fluoro-D-glucosa]]></kwd>
<kwd lng="es"><![CDATA[tomografía computarizada]]></kwd>
<kwd lng="en"><![CDATA[lymphomas]]></kwd>
<kwd lng="en"><![CDATA[staging]]></kwd>
<kwd lng="en"><![CDATA[positron emission tomography]]></kwd>
<kwd lng="en"><![CDATA[18F-2-deoxy-2-fluoro-D-glucose]]></kwd>
<kwd lng="en"><![CDATA[computed tomography]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sir Godfrey Newbold Hounsfield y la tomografía computada, su contribución a la medicina moderna]]></article-title>
<source><![CDATA[Rev Chil Radiol]]></source>
<year>2004</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>183-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beckmann]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CT scanning the early days]]></article-title>
<source><![CDATA[Br J Radiol]]></source>
<year>2006</year>
<volume>79</volume>
<page-range>5-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lovera]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de Medicina Nuclear]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tomografía por emisión de positrones (PET): evolución y futuro]]></article-title>
<source><![CDATA[Radiobiología]]></source>
<year>2007</year>
<volume>7</volume>
<page-range>148-56</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beyer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Townsend]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Brun]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kinahan]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Charron]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Roddy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A combined PET/CT scanner for clinical oncology]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2000</year>
<volume>41</volume>
<page-range>1369-79</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martí-Climent]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Serra]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Boán]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Richter]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tomografía por emisión de positrones con un equipo PET/TAC]]></article-title>
<source><![CDATA[Rev Esp Med Nucl]]></source>
<year>2005</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>60-79</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Press]]></surname>
<given-names><![CDATA[OW]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtman]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[General considerations for Lymphomas: Epidemiology, Etiology, Heterogeneity, Primary Extranodal Disease]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Kaushansky]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtman]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Prchal]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Press]]></surname>
<given-names><![CDATA[OW]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Williams Hematology]]></source>
<year>2016</year>
<edition>9</edition>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill Education]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carbone]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Musshoff]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Report of the Committee on Hodgkin's Disease Staging Classification]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1971</year>
<volume>31</volume>
<page-range>1860-1</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lister]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Crowther]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sutcliffe]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Glatstein]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Canellos]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease Cotswolds meeting]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1989</year>
<volume>7</volume>
<page-range>1630-66</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheson]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Horning]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Coiffier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shipp]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group]]></article-title>
<collab>Connors JM et al</collab>
<source><![CDATA[J Clin Oncol]]></source>
<year>1999</year>
<volume>17</volume>
<page-range>2454-60</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheson]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Pfistner]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Juweid]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Gascoyne]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Spetch]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Horning]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revised response criteria for malignant lymphoma]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2007</year>
<volume>25</volume>
<page-range>579-86</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kostakoglu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cheson]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current role of FDG PET/CT in lymphoma]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2014</year>
<volume>41</volume>
<page-range>1004-27</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrington]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Mikhaeel]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Kostakoglu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Meignan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martin Hutchings]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of imaging in the staging and response assessment of lymphoma Consensus of the International Conference on Malignant Lymphomas Imaging Working Group]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>3048-58</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheson]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
<name>
<surname><![CDATA[Barrington]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Cavalli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Zucca]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma The Lugano classification]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>3059-68</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kostakoglu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guest editorial]]></article-title>
<source><![CDATA[Semin Nucl Med]]></source>
<year>2018</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-3</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Galaly]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Gormsen]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchings]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PET/CT for Staging; Past, Present, and Future]]></article-title>
<source><![CDATA[Semin Nucl Med]]></source>
<year>2018</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-16</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrillo-Cruz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Marín-Oyaga]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[de la Cruz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Borrego-Dorado]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Acevedo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma]]></article-title>
<source><![CDATA[Hematol Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>151-68</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bosio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Giubbini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bertagna]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[18F-FDG PET/CT and extragastric MALT lymphoma Role of Ki-67 score and plasmacytic differentiation]]></article-title>
<source><![CDATA[Leuk Lymphoma]]></source>
<year>2017</year>
<volume>58</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2328-34</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novelli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Briones]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Flotats]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PET/CT assessment of follicular lymphoma and high grade B cell lymphoma-Good correlation with clinical and histological features at diagnosis]]></article-title>
<source><![CDATA[Adv Clin Exp Med]]></source>
<year>2015</year>
<volume>24</volume>
<page-range>325-30</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrington]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkwood]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Franceschetto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fulham]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Almquist]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PET-CT for staging and early response results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2016</year>
<volume>127</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1531-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cerci]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bogoni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Buccheri]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sa de Camargo]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Bruno]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Baiochi]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fluorodeoxy glucosa - positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma Results from the Brasilian Hodgkin's Lymphoma Study Group]]></article-title>
<source><![CDATA[Hematol Transfus Cell Ther]]></source>
<year>2018</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>245-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boellaard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado-Bolton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Oyen]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Giammarile]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tatsch]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FDG PET/CT EANM procedure guidelines for tumour imaging: Version 2.0]]></article-title>
<collab>Eschner W et a</collab>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2015</year>
<volume>42</volume>
<page-range>328-54</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kostakoglu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chauvie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic Tumor Volume Metrics in Lymphoma]]></article-title>
<source><![CDATA[Semin Nucl Med]]></source>
<year>2018</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-66</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
